Figure 1






Figure 2

A.



B.



C.





Figure 3

A.


x10 4
Reduced
Heavy Chain
+0 Dex-
Linker
+1 Dex-
Linker
+2 Dex-
Linker
50635.00
50650.26
51665.28
51849.68
52674.42
52832.87
Counts vs. Deconvoluted Mass (amu)

B.




x10 5
Reduced
Light Chain
23444.30
Counts vs. Deconvoluted Mass (amu)


Figure 4



R1, R2, R3= H, CH3
n= 1, 2
m= 0, 1

1. Evaluation of spacers: R1, R2 = H, CH3
n= 1, 2

1st run examples:



2. Evaluation of dipeptides with fixed miniPEA linker:

Val-Cit, Val/Phe-Lys, Val-Glu, Val-Asp

1st run examples:




Figure 5




Figure 6




Figure 7



Dexamethasone
Budesonide
Mometasone furoate
Fluticasone furoate
Receptor affinity:
100
855
2245
2989

Figure 8




Figure 9



BocHN
NH2
NHBoc
1-3
2-1
2-2
Fmoc-Val-Cit-PAB-PNP
NHFmoc
2-3
Fmoc
2-4
2-5
2-6
2-7

Figure 10




Figure 11




Figure 12




Figure 13

